PD-1 (Programmed cell death 1) • BCL6 (B-cell CLL/lymphoma 6) • LAG3 (Lymphocyte Activating 3) • CD38 (CD38 Molecule) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CCR7 (Chemokine (C-C motif) receptor 7) • GZMB (Granzyme B) • BTLA (B And T Lymphocyte Associated) • PRDM1 (PR/SET Domain 1) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • SIGLEC15 (Sialic Acid Binding Ig Like Lectin 15)

paclitaxel • nanoencapsulated paclitaxel (FID-007)

8ms

HNSCC: FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)

P2, N=46, Recruiting, Fulgent Pharma LLC. | Not yet recruiting --> Recruiting

8 months ago

Enrollment open • Combination therapy • Metastases

Erbitux (cetuximab) • paclitaxel • nanoencapsulated paclitaxel (FID-007)

9ms

FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer (clinicaltrials.gov)

P1, N=10, Not yet recruiting, University of Southern California

9 months ago

New P1 trial • Surgery

paclitaxel • nanoencapsulated paclitaxel (FID-007)

10ms

FID-007 in Treating Participants With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=36, Recruiting, University of Southern California | Trial completion date: May 2025 --> May 2026 | Trial primary completion date: May 2024 --> May 2025

10 months ago

Trial completion date • Trial primary completion date • Metastases

paclitaxel • nanoencapsulated paclitaxel (FID-007)

1year

Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting (Businesswire)

"Fulgent Genetics, Inc...announced two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, to be held virtually and at the San Diego Convention Center from November 1 to 5, 2023."

1 year ago

Clinical data • Clinical

nanoencapsulated paclitaxel (FID-007)

2years

Fulgent Genetics Acquires Fulgent Pharma, Creating a New Paradigm in Precision Medicine for The Company (Fulgent Genetics Press Release)

"Fulgent Genetics...announced today that it has completed an acquisition of Fulgent Pharma Holdings, Inc. ('Fulgent Pharma'), an independent clinical-stage, therapeutics development company focused on the development of innovative cancer treatments. Under the terms of the agreement, Fulgent Genetics acquired Fulgent Pharma for a total purchase price of approximately $100 million, subject to adjustments, to be paid with a combination of cash on hand and shares of common stock of Fulgent Genetics. The combined company plans to offer a vertically integrated solution to combat cancer with the potential to unlock significant long-term upside for both the therapeutic and diagnostic businesses, while effectively managing risk....Attractive Lead Therapeutic Candidate FID-007...is a proprietary nanoencapsulated formulation of paclitaxel developed to improve the overall solubility profile of paclitaxel."

2 years ago

M&A

nanoencapsulated paclitaxel (FID-007)